Next Article in Journal
Initial Evaluation of Prospective and Parallel Assessments of Cystic Fibrosis Newborn Screening Protocols in Eastern Andalusia: IRT/IRT versus IRT/PAP/IRT
Previous Article in Journal
Newborn Sickle Cell and Thalassaemia Screening Programme: Automating and Enhancing the System to Evaluate the Screening Programme
Open AccessArticle

The Reliable, Automatic Classification of Neonates in First-Tier MALDI-MS Screening for Sickle Cell Disease

1
Biomaneo, 22B boulevard Winston Churchill, F-21000 Dijon, France
2
Newborn Screening Laboratory, Biology and Pathology Center, Lille University Medical Centre, F-59000 Lille, France
*
Author to whom correspondence should be addressed.
Int. J. Neonatal Screen. 2019, 5(3), 31; https://doi.org/10.3390/ijns5030031
Received: 25 June 2019 / Revised: 16 August 2019 / Accepted: 18 August 2019 / Published: 31 August 2019
Previous research has shown that a MALDI-MS technique can be used to screen for sickle cell disease (SCD), and that a system combining automated sample preparation, MALDI-MS analysis and classification software is a relevant approach for first-line, high-throughput SCD screening. In order to achieve a high-throughput “plug and play” approach while detecting “non-standard” profiles that might prompt the misclassification of a sample, we have incorporated various sets of alerts into the decision support software. These included “biological alert” indicators of a newborn’s clinical status (e. g., detecting samples with no or low HbA), and “technical alerts” indicators for the most common non-standard profiles, i.e., those which might otherwise lead to sample misclassification. We evaluated these alerts by applying them to two datasets (produced by different laboratories). Despite the random generation of abnormal spectra by one-off technical faults or due to the nature and quality of the samples, the use of alerts fully secured the process of automatic sample classification. Firstly, cases of β-thalassemia were detected. Secondly, after a visual check on the tagged profiles and reanalysis of the corresponding biological samples, all the samples were correctly reclassified without prompting further alerts. All of the samples for which the results were not tagged were well classified (i.e., sensitivity and specificity = 1). The alerts were mainly designed for detecting false-negative classifications; all the FAS samples misclassified by the software as FA (a false negative) were marked with an alert. The implementation of alerts in the NeoScreening® Laboratory Information Management System’s decision support software opens up perspectives for the safe, reliable, automated classification of samples, with a visual check solely on abnormal results or samples. It should now be possible to evaluate the combination of the NeoSickle® analytical solution and the NeoScreening® Laboratory Information Management System in a real-life, prospective study of first-line SCD screening. View Full-Text
Keywords: sickle cell disease; MALDI-MS; automatic classification; software; β-thalassemia; high-throughput SCD screening; Laboratory Information Management System (LIMS) sickle cell disease; MALDI-MS; automatic classification; software; β-thalassemia; high-throughput SCD screening; Laboratory Information Management System (LIMS)
Show Figures

Figure 1

MDPI and ACS Style

El Osta, M.; Naubourg, P.; Grunewald, O.; Renom, G.; Ducoroy, P.; Périni, J.M. The Reliable, Automatic Classification of Neonates in First-Tier MALDI-MS Screening for Sickle Cell Disease. Int. J. Neonatal Screen. 2019, 5, 31.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop